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Essay
D
isease mongering is the 
selling of sickness that widens 
the boundaries of illness in 
order to grow markets for those who 
sell and deliver treatments. It is a 
process that turns healthy people into 
patients, causes iatrogenic harm, and 
wastes precious resources [1]. Disease 
mongering is the contemporary form 
of “medicalisation.” It is a process 
now driven by both corporate and 
professional interests, and it has 
become part of the global debate about 
health care. International consumer 
groups now target drug company–
backed disease mongering as a wasteful 
threat to public health [2], while the 
global pharmaceutical industry has 
been forced to defend its promotion of 
“lifestyle” medicines for problems like 
slimming and sexual difﬁ  culties [3].
Two years ago, we helped organise 
the world’s ﬁ  rst international 
conference on disease mongering in 
Newcastle, Australia, which coincided 
with a special theme issue of PLoS 
Medicine on the same subject [4]. The 
combination of these events sparked 
signiﬁ  cant media interest around 
the world [5,6] and helped bring 
global attention to the problem of 
disease mongering. This attention has 
been sustained. Disease mongering 
increasingly appears in media analyses 
of medical conditions and new 
treatments. It has a page devoted to it 
on Wikipedia [7], and was recently the 
subject of a much publicised award-
winning work of art [8]. In this short 
Essay, we report brieﬂ  y on the inaugural 
conference, discuss its subsequent 
impact, and raise possible directions for 
academic inquiry and policy reform.
The Inaugural Conference on 
Disease Mongering
The three-day conference was attended 
by approximately 150 national and 
international delegates, including 
academics, consumer advocates, 
journalists, public relations experts, 
and health professionals. Combining 
plenaries and smaller sessions, the 
conference heard 44 presentations, 
including many examples of disease 
mongering that have subsequently 
received more public attention. 
New York University academic 
psychiatrist Leonore Tiefer spoke about 
the involvement of drug companies 
in helping to foster the creation of a 
new condition called female sexual 
dysfunction [9]. Cardiff University 
psychiatrist David Healy charted the 
growing promotion of bipolar disorder 
and drugs to treat it [10]. Dartmouth 
University researchers Lisa Schwartz 
and Steven Woloshin revealed how the 
prevalence of restless legs syndrome was 
being exaggerated to broaden markets 
for new drugs [11]. One of the most 
popular sessions of the conference was 
the opening plenary, which featured 
the ﬁ  ctional Professor Leth Argos 
discussing a satirical “new” disease 
called motivational deﬁ  ciency disorder, 
said to affect up to one in ﬁ  ve people 
worldwide [12].  Part of his presentation 
is available on YouTube [13].
The conference concluded with a 
short statement, communicated to 
the public via the media. It strongly 
supported the use of appropriate 
therapeutic and preventative 
treatments, but expressed concern 
that many therapies were increasingly 
being promoted for milder and milder 
conditions, leading to potentially 
unnecessary treatment, adverse effects, 
and wasted resources. The brief 
statement also called for research and 
policy action to help people recognise 
the signs of disease mongering, and 
thus enable the public to make more 
informed choices about their health. 
The Impact of the Inaugural 
Conference and the PLoS Theme 
Issue
A systematic study of the impact of 
the conference and theme issue is 
beyond the scope of this short report. 
Notwithstanding our scepticism about 
the value of anecdotal evidence, and 
the inadequacy of surrogate markers, 
we feel there are reliable signs that 
disease mongering is now part of 
the global health debate. Within the 
media, consumer movements, and the 
professional and research communities, 
increasing numbers of people are 
formulating ways to confront the 
problem, in some cases forcing the 
pharmaceutical industry to respond.
In the United States, which is 
responsible for roughly half of all 
global spending on prescription 
medicines, a leading media watch 
organisation now routinely analyses 
health news stories for any signs of 
disease mongering [14]. Created 
in 2006 in the US, and inspired by 
similar organisations in Australia 
and Canada, HealthNewsReview.org 
(http://HealthNewsReview.org/) tries 
to encourage journalists writing about 
health not to contribute to the process 
of medicalising ordinary life [15]. The 
emergence of high-proﬁ  le articles on 
the subject also suggests scepticism 
is building within the mainstream 
media. In covering a new drug called 
Requip—for “restless legs syndrome”—
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The Wall Street Journal headlined the 
story “How Glaxo Marketed a Malady 
to Sell a Drug” [16]. Similarly, The New 
York Times recently ran a story about 
a new medicine called Lyrica—for 
“ﬁ  bromyalgia”—under the headline 
“Drug Approved. Is Disease Real?” 
[17]. 
In November 2007, disease 
mongering was a key subject of debate 
at the annual congress of Consumers 
International, an organisation 
involving 220 member groups in over 
100 countries. Responding to the 
issue at that conference, the head 
of the International Federation of 
Pharmaceutical Manufacturers and 
Associations, Harvey Bale, conceded 
that there were examples of “egregious 
over-promotion”, but defended 
the industry’s capacity to ethically 
market medicines [18]. In Britain, 
the industry’s representative body 
has been forced to react directly to 
burgeoning media interest in the role 
drug companies play in expanding 
deﬁ  nitions of disease. In a two-page 
pamphlet for journalists, the industry 
points out that while the total number 
of diseases is growing, drug companies 
do not actually deﬁ  ne them [3]. 
Similarly, Glaxo has denied that its 
promotion of a drug for restless legs 
syndrome is an attempt to turn healthy 
people into patients [19].
In the academic arena, several 
developments suggest an increasing 
interest in this phenomenon. In 
Scotland last year, at a conference 
at the University of Strathclyde 
on Communication and Conﬂ  ict, 
researchers and academics from 
around the world gathered to debate 
disease mongering, as they had in 
Newcastle a year before [20]. In Spain, 
a group of researchers based at the 
University of Alicante are studying the 
problem as part of a wider look at drug 
company advertisements. With funding 
from the Spanish government, this 
group is planning a national campaign 
against disease mongering (personal 
communication, R. Moynihan). 
Elsewhere, the Australian Research 
Council, through its competitive grant 
processes, has funded a two-year study 
of disease mongering, which will be 
conducted by the authors of this paper 
[21]. 
The Australian project will 
investigate and describe several case 
studies of disease mongering, and 
we plan to disseminate our results 
via published articles and video 
material. Signiﬁ  cantly, the approach 
will combine academic inquiry with 
investigative journalism. While we 
argue that the phenomenon of disease 
mongering demands more academic 
attention, such inquiry throws up major 
methodological challenges. To begin 
to address these challenges, the ﬁ  rst 
phase of the research will be devoted 
to establishing a sound operational 
deﬁ  nition of disease mongering before 
moving to the careful selection of 
cases for detailed study. Part of the 
problem is the sheer magnitude of 
the marketing effort in an industry 
that spends almost 25% of its sales on 
promotion—almost twice as much as it 
spends on research and development 
[22].  The process of extending 
the boundaries of illness involves 
many differing marketing strategies, 
including television advertisements 
for lifestyle drugs, drug company–
orchestrated disease-awareness 
campaigns, and the funding of patient 
and physician groups. Describing the 
size of the problem, and measuring 
its impact on physician behaviour or 
health outcomes, while desirable, may 
prove extremely difﬁ  cult. 
Future Directions
As public interest in the corporate-
sponsored creation of disease grows, 
the need for a central database or 
resource library is becoming clearer. 
A credible Web site attached to an 
academic or advocacy group featuring 
case studies and other information 
on disease mongering could prove 
very valuable. Already some groups, 
including Healthy Skepticism (http://
healthyskepticism.org/), have devoted 
space to this debate, and others are 
likely to follow. 
While we have noted some signs 
of media, consumer, and academic 
debate and action about the problem 
of disease mongering, we are not aware 
of a similar increase in policy interest 
or action. In fact, to the contrary, 
there is some evidence of complacency 
about disease mongering on the part 
of regulators. The US Food and Drug 
Administration’s recent proposal to 
relax restrictions on off-label marketing 
risked setting the conditions for 
disease mongering to ﬂ  ourish [23]. 
Unnecessary medicalisation and 
medication may be wasting many 
precious health resources, with obvious 
opportunity costs for private and 
public health insurers alike. Producing 
credible estimates of the magnitude 
of those costs is a future direction that 
should be urgently pursued.  
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